Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS

Neuroimmune activation as a novel therapeutic approach for IBD

Obiettivo

NeurIMM has been designed to investigate the commercial and technical viability of a novel, targeted therapy for Inflammatory Bowel Disease (IBD), based on a recently uncovered signaling axis between intestinal type 3 innate lymphoid cells (ILC3s) and enteric glial cells. This discovery by the team of Prof. Henrique Veiga-Fernandes in the ERC CoG grant 647274 ‘GliaInnateSensing’ was recently published in Nature (Ibiza et al, Nature 2016). NeurIMM proposes the use of a glial cell-derived immunomodulator to restore intestinal homeostasis, by inducing a tissue protective immune response. Importantly, this novel therapy will also promote tissue healing to reverse immune-cell mediated tissue damage, leading to improved outcomes for the patient. This could have major implications for patients suffering from IBD. In addition, this approach also has potential as an effective therapy against cancer, (pediatric) gastroenteritis, and other inflammatory disorders.

Campo scientifico (EuroSciVoc)

Programma(i)

Argomento(i)

Meccanismo di finanziamento

ERC-POC - Proof of Concept Grant

Vedi tutti i progetti finanziati nell’ambito di questo schema di finanziamento

Invito a presentare proposte

(si apre in una nuova finestra) ERC-2017-PoC

Vedi tutti i progetti finanziati nell’ambito del bando

Istituzione ospitante

FUNDACAO D. ANNA DE SOMMER CHAMPALIMAUD E DR. CARLOS MONTEZ CHAMPALIMAUD
Contributo netto dell'UE
€ 150 000,00
Indirizzo
AVENIDA BRASILIA, CENTRO DE INVESTIGACAO DA FUNDACAO CHAMPALIMAUD
1400-038 LISBOA
Portogallo
Tipo di attività
Research Organisations
Collegamenti
Costo totale
€ 150 000,00

Beneficiari (1)